Graves’ Ophthalmopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Graves’ Ophthalmopathy Pipeline Drugs Market Report Overview

Graves’ ophthalmopathy is an autoimmune condition where the thyroid gland mistakenly senses harmful cells and releases antibodies to combat them. Since there are no harmful cells, the released antibodies end up fusing with muscles in the eyes, causing the onset of Graves‘ ophthalmopathy. Symptoms include eye redness, inflammation, eyelid retraction, and weakness. Treatment includes radioiodine therapy, anti-thyroid medications, and thyroid surgery.

The Graves’ Opththalmopathy pipeline drugs market research report provides comprehensive information on the therapeutics under development for Graves’ Opththalmopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Graves’ Opththalmopathy and features dormant and discontinued projects.

Graves’ Opththalmopathy Pipeline Drugs Market Segmentation by Targets

The key targets in the Graves’ Opththalmopathy pipeline drugs market are Insulin Like Growth Factor 1 Receptor, IgG Receptor FcRn Large Subunit p51, Interleukin 17A, Glucocorticoid Receptor, and others.  Insulin Like Growth Factor 1 Receptor has the highest number of products in development in the Graves’ Opththalmopathy pipeline drugs market in 2022.

Graves’ Opththalmopathy Pipeline Drugs Market Analysis by Targets

For more target insights into the Graves’ Opththalmopathy pipeline drugs market, download a free report sample

Graves’ Opththalmopathy Pipeline Drugs Market Segmentation by Mechanisms of Action

The key mechanisms of action in the Graves’ Opththalmopathy pipeline drugs market are Insulin Like Growth Factor 1 Receptor Antagonist, Insulin Like Growth Factor 1 Receptor Inhibitor, IgG Receptor FcRn Large Subunit p51 Antagonist, Interleukin 17A Inhibitor, and others. Insulin Like Growth Factor 1 Receptor Antagonist leads the Graves’ Opththalmopathy pipeline drugs market in terms of MoA.

Graves’ Opththalmopathy Pipeline Drugs Market Analysis by Mechanisms of Action

For more MoA insights into the Graves’ Opththalmopathy pipeline drugs market, download a free report sample

Graves’ Opththalmopathy Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Graves’ Opththalmopathy pipeline drugs market are subcutaneous, intravenous, intramuscular, intravenous drip, and others. The subcutaneous RoA has the highest number of Graves’ Opththalmopathy drugs in development in 2022.

Graves’ Opththalmopathy Pipeline Drugs Market Analysis by Routes of Administration

For more RoA insights into the Graves’ Opththalmopathy pipeline drugs market, download a free report sample

Graves’ Opththalmopathy Pipeline Drugs Market Segmentation by Molecule Types

The key molecule types in the Graves’ Opththalmopathy pipeline drugs market are monoclonal antibody, biologic, fusion protein, small molecule, and synthetic peptide. Monoclonal antibody leads the Graves’ Opththalmopathy pipeline drugs market in terms of molecule type.

Graves’ Opththalmopathy Pipeline Drugs Market Analysis by Molecule Types

For more molecule type insights into the Graves’ Opththalmopathy drugs market, download a free report sample

Graves’ Opththalmopathy Pipeline Drugs Market - Competitive Landscape

Some of the leading companies in the Graves’ Opththalmopathy pipeline drugs market are Genmab AS, Viridian Therapeutics Inc, HanAll Biopharma Co Ltd, and ImmunoGen Inc. Genmab AS and Viridian Therapeutics Inc accounted for the highest number of Graves’ Opththalmopathy drugs in development in 2022.

Graves’ Opththalmopathy Pipeline Drugs Market Analysis by Companies

To know more about the leading Graves’ Opththalmopathy pipeline drugs market players, download a free report sample

Graves’ Opththalmopathy Pipeline Products Market Overview

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Graves’ Opththalmopathy.
• The pipeline guide reviews pipeline therapeutics for Graves’ Opththalmopathy by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Graves’ Opththalmopathy therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Graves’ Opththalmopathy therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews the latest news related to pipeline therapeutics for Graves’ Opththalmopathy

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Graves’ Opththalmopathy.
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding the Graves’ Opththalmopathy pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.